文献速递泌尿男性生殖肿瘤

替沃扎尼在索拉非尼治疗后晚期肾细胞癌患者中的疗效:III期研究交叉部分

Efficacy of tivozanib treatment after sorafenib in patients with advanced renal cell carcinoma: crossover of a phase 3 study.
PubMed 文献 · Eur J Cancer · 2018-03-20

本开放标签、交叉II期研究(AV-951-09-902)纳入TIVO-1中随机接受索拉非尼后进展的晚期肾细胞癌患者,交叉接受替沃扎尼(1.5 mg/日,服3周停1周)治疗。结果显示中位无进展生存期11.0个月(95%CI 7.3-12.7),中位总生存期21.6个月(95%CI 17.0-27.6),部分缓解率18%,疾病稳定率52%。安全性可接受,与替沃扎尼已知不良事件谱一致。

要点

  • 索拉非尼进展后交叉替沃扎尼,中位PFS 11.0个月,中位OS 21.6个月。
  • 部分缓解18%,疾病稳定52%,中位缓解持续时间分别为15.2和12.7个月。
  • 常见不良事件为高血压(26%)、腹泻(14%)和乏力(13%);24%出现≥3级治疗相关不良事件。

核心结论

  • 在晚期肾细胞癌患者中,索拉非尼治疗后进展再接受替沃扎尼交叉治疗显示出较强的抗肿瘤活性。
  • 替沃扎尼的安全性和耐受性可接受,与已知不良事件谱一致。

研究设计与样本

  • 开放标签、单臂、II期交叉临床研究(AV-951-09-902)。
  • 纳入TIVO-1中随机分配至索拉非尼后进展并交叉至替沃扎尼的晚期肾细胞癌患者。
  • 替沃扎尼给药方案为1.5 mg/日口服,服3周停1周,于末次索拉非尼给药后4周内开始。

主要发现

  • 交叉患者接受替沃扎尼治疗的中位周期数为8个。
  • 自替沃扎尼治疗开始,中位无进展生存期为11.0个月(95%CI 7.3-12.7),中位总生存期为21.6个月(95%CI 17.0-27.6)。
  • 最佳总缓解为部分缓解29例(18%),疾病稳定83例(52%),中位缓解持续时间分别为15.2个月和12.7个月。
  • 约77%的患者发生不良事件,最常见为高血压(26%)、腹泻(14%)和乏力(13%);53%发生治疗相关不良事件,其中24%为≥3级。
  • 约9%和16%的患者因不良事件分别进行剂量减少和剂量中断;30%发生严重不良事件,4%发生治疗相关严重不良事件。

临床怎么用

  • 对于索拉非尼治疗后进展的晚期肾细胞癌患者,替沃扎尼交叉治疗可作为一种治疗选择,需关注高血压、腹泻和乏力等不良事件。

局限性

  • 本研究为单臂、II期交叉研究,未设对照,样本量有限。
  • 交叉设计可能存在选择偏倚,结果需进一步验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Tivozanib is a selective inhibitor of vascular endothelial growth factor receptors 1, 2 and 3 tyrosine kinases. This open-label, crossover clinical study (AV-951-09-902) provided access to tivozanib for patients who progressed on sorafenib in TIVO-1, comparing tivozanib with sorafenib in patients with advanced renal cell carcinoma (RCC). METHODS: Patients enrolled in this single-arm, phase 2 crossover study were previously randomised to sorafenib on TIVO-1, progressed and then crossed over to tivozanib. Patients received tivozanib (1.5 mg/day orally; 3 weeks on/1 week off) within 4 weeks after their last sorafenib dose. FINDINGS: Crossover patients were exposed to tivozanib for a median of eight cycles. From the start of tivozanib treatment, median progression-free survival was 11.0 months (95% confidence interval [CI]: 7.3-12.7) and median overall survival was 21.6 months (95% CI: 17.0-27.6). Best overall response was partial response in 29 (18%) patients and stable disease in 83 (52%) patients, with a median duration of response of 15.2 and 12.7 months, respectively. About 77% of patients experienced adverse events, most frequently hypertension (26%), followed by diarrhoea (14%) and fatigue (13%); 53% of patients had treatment-related adverse events, including 24% grade ≥3. About 9% and 16% of patients had dose reductions and dose interruptions due to adverse events, respectively. A total of 30% of patients had serious adverse events, and 4% had treatment-related serious adverse events. INTERPRETATION: This crossover study of patients with advanced RCC demonstrated potent tivozanib anti-tumour activity. Safety and tolerability profiles were acceptable and consistent with the established adverse event profile of tivozanib.

来源:Eur J Cancer,查看原文。版权归原作者所有。

引用

  1. Molina AM, Hutson TE, Nosov D, et al. Efficacy of tivozanib treatment after sorafenib in patients with advanced renal cell carcinoma: crossover of a phase 3 study. Eur J Cancer. 2018. PMID: 29547835. doi:10.1016/j.ejca.2018.02.009

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。